NASDAQ:BCRX - BioCryst Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.36
  • Forecasted Upside: 108.68 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$8.80
▲ +0.23 (2.68%)

This chart shows the closing price for BCRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioCryst Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCRX

Analyst Price Target is $18.36
▲ +108.68% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for BioCryst Pharmaceuticals in the last 3 months. The average price target is $18.36, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 108.68% upside from the last price of $8.80.

This chart shows the closing price for BCRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 investment analysts is to buy stock in BioCryst Pharmaceuticals. This rating has held steady since July 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/26/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
2/24/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
4/25/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2022OppenheimerLower Price TargetOutperform ➝ Outperform$16.00 ➝ $13.00Medium
5/9/2022Cantor FitzgeraldReiterated RatingOverweightLow
5/5/2022Piper SandlerLower Price Target$24.00 ➝ $19.00Low
4/18/2022BarclaysDowngradeOverweight ➝ Equal Weight$22.00 ➝ $13.00Medium
4/12/2022Royal Bank of CanadaLower Price TargetSector Perform$16.00 ➝ $14.00Low
4/11/2022OppenheimerLower Price TargetOutperform$20.00 ➝ $16.00High
4/11/2022Bank of AmericaDowngradeBuy ➝ Neutral$21.00 ➝ $14.00High
4/8/2022Evercore ISILower Price Target$25.00 ➝ $15.00High
2/24/2022HC WainwrightReiterated RatingBuy$30.00Medium
2/24/2022BarclaysBoost Price Target$17.00 ➝ $22.00High
2/23/2022Piper SandlerReiterated RatingIn-Line$24.00Low
1/11/2022HC WainwrightReiterated RatingBuy$30.00High
12/9/2021OppenheimerInitiated CoverageOutperform$16.00Medium
11/4/2021Royal Bank of CanadaLower Price TargetSector Perform$16.00 ➝ $14.00High
11/4/2021BarclaysLower Price TargetOverweight$21.00 ➝ $17.00High
9/16/2021JMP SecuritiesReiterated RatingBuy$23.00Low
8/6/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$19.00Low
8/6/2021Royal Bank of CanadaBoost Price TargetSector Perform$13.00 ➝ $16.00Low
8/6/2021JMP SecuritiesBoost Price TargetMarket Outperform$22.00 ➝ $23.00High
8/6/2021BarclaysBoost Price TargetOverweight$20.00 ➝ $21.00Low
8/6/2021HC WainwrightBoost Price TargetBuy$18.00 ➝ $30.00Low
8/5/2021Piper SandlerBoost Price TargetOverweight$18.00 ➝ $22.00Low
8/3/2021Cantor FitzgeraldInitiated CoverageOverweight$21.00Medium
6/17/2021CowenBoost Price TargetOutperform$18.00 ➝ $21.00Low
5/28/2021Piper SandlerBoost Price TargetOverweight$15.00 ➝ $18.00High
5/7/2021Evercore ISIBoost Price Target$16.00 ➝ $20.00Medium
5/7/2021BarclaysBoost Price TargetOverweight$13.00 ➝ $20.00High
4/15/2021Needham & Company LLCReiterated RatingHoldHigh
3/24/2021HC WainwrightBoost Price TargetBuy$14.00 ➝ $19.00High
3/17/2021JPMorgan Chase & Co.Boost Price TargetPositive ➝ Overweight$10.00 ➝ $15.00Medium
3/1/2021CowenInitiated CoverageOutperform$16.00Low
2/26/2021BarclaysBoost Price TargetOverweight$9.00 ➝ $13.00Low
1/22/2021Royal Bank of CanadaBoost Price TargetSector Perform$7.00 ➝ $9.00High
12/7/2020HC WainwrightBoost Price TargetBuy$13.00 ➝ $14.00High
11/23/2020Evercore ISIInitiated CoverageOutperform$12.00High
10/4/2020Bank of AmericaReiterated RatingBuy$6.00High
9/29/2020JPMorgan Chase & Co.Initiated CoverageOverweightMedium
8/28/2020Royal Bank of CanadaReiterated RatingHold$4.50High
8/7/2020HC WainwrightReiterated RatingBuy$13.00Low
7/6/2020Royal Bank of CanadaReiterated RatingHold$5.00Low
6/26/2020JMP SecuritiesBoost Price TargetOutperform$10.00 ➝ $11.00High
6/16/2020BTIG ResearchInitiated CoverageNeutralHigh
6/8/2020Piper SandlerReiterated RatingBuy$10.00Medium
5/7/2020Royal Bank of CanadaReiterated RatingHold$4.00Low
5/6/2020Needham & Company LLCReiterated RatingHoldLow
5/6/2020Piper SandlerBoost Price Target$8.00 ➝ $10.00Medium
5/5/2020BarclaysUpgradeEqual Weight ➝ Overweight$4.00 ➝ $7.00High
3/9/2020Needham & Company LLCReiterated RatingHoldHigh
11/15/2019Bank of AmericaUpgradeNeutral ➝ Buy$5.00 ➝ $4.00Low
11/6/2019Needham & Company LLCReiterated RatingHoldMedium
10/31/2019HC WainwrightReiterated RatingBuy$13.00High
5/24/2019Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$16.00 ➝ $4.50Low
5/23/2019JMP SecuritiesLower Price TargetOutperform$18.00 ➝ $10.00High
5/22/2019Jefferies Financial GroupLower Price TargetBuy$13.00 ➝ $8.00High
5/22/2019HC WainwrightReiterated RatingBuyMedium
4/22/2019Piper Jaffray CompaniesSet Price TargetBuy$15.00Medium
4/2/2019JMP SecuritiesBoost Price TargetMarket Outperform ➝ Market Outperform$16.00 ➝ $18.00High
4/2/2019BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$6.00 ➝ $8.00High
12/4/2018Royal Bank of CanadaBoost Price TargetOutperform ➝ Positive$16.00High
11/16/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$15.00High
9/5/2018JMP SecuritiesBoost Price TargetOutperform$12.00 ➝ $16.00High
8/13/2018HC WainwrightReiterated RatingBuy$13.00Medium
8/9/2018Jefferies Financial GroupReiterated RatingBuy$8.50High
8/8/2018JPMorgan Chase & Co.Initiated CoverageOverweight$9.00Medium
8/7/2018Royal Bank of CanadaReiterated RatingBuy$9.00High
7/17/2018Bank of AmericaUpgradeUnderperform ➝ NeutralMedium
1/23/2018HC WainwrightReiterated RatingBuy$10.00Medium
1/2/2018Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$6.00High
12/20/2017BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$6.00Medium
11/8/2017HC WainwrightReiterated RatingBuy$10.00N/A
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$6.00Low
9/6/2017HC WainwrightReiterated RatingBuy$10.00High
9/6/2017JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Neutral$4.93 ➝ $9.00High
9/6/2017Jefferies Financial GroupUpgradeHold ➝ Buy$5.00 ➝ $7.00High
9/5/2017JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$6.00 ➝ $9.00High
9/5/2017Piper Jaffray CompaniesReiterated RatingOverweight$13.00 ➝ $15.00High
8/8/2017Noble FinancialReiterated RatingBuyLow
8/8/2017HC WainwrightReiterated RatingBuyLow
5/28/2017Noble FinancialReiterated RatingBuyLow
(Data available from 5/25/2017 forward)

News Sentiment Rating

0.08 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/27/2021
  • 5 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/26/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2021
  • 3 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
1/25/2022
  • 1 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
2/24/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/26/2022
  • 1 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
4/25/2022
  • 3 very positive mentions
  • 14 positive mentions
  • 8 negative mentions
  • 1 very negative mentions
5/25/2022

Current Sentiment

  • 3 very positive mentions
  • 14 positive mentions
  • 8 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

BioCryst Pharmaceuticals logo
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $8.80
Low: $8.45
High: $8.83

50 Day Range

MA: $11.97
Low: $7.89
High: $17.88

52 Week Range

Now: $8.80
Low: $7.61
High: $19.99

Volume

2,199,140 shs

Average Volume

4,736,477 shs

Market Capitalization

$1.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.51

Frequently Asked Questions

What sell-side analysts currently cover shares of BioCryst Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on BioCryst Pharmaceuticals in the last twelve months: Bank of America Co., Barclays PLC, Cantor Fitzgerald, Cowen Inc, Evercore ISI, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, StockNews.com, and Zacks Investment Research.
View the latest analyst ratings for BCRX.

What is the current price target for BioCryst Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for BioCryst Pharmaceuticals in the last year. Their average twelve-month price target is $18.36, suggesting a possible upside of 108.7%.
View the latest price targets for BCRX.

What is the current consensus analyst rating for BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals currently has 5 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BCRX will outperform the market and that investors should add to their positions of BioCryst Pharmaceuticals.
View the latest ratings for BCRX.

How do I contact BioCryst Pharmaceuticals' investor relations team?

BioCryst Pharmaceuticals' physical mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company's listed phone number is (919) 859-1302 and its investor relations email address is [email protected] The official website for BioCryst Pharmaceuticals is www.biocryst.com. Learn More about contacing BioCryst Pharmaceuticals investor relations.